MASH vs. MASLD: Which Medications Are Actually FDA Approved for Weight Loss? | Dr Mauricio Gonzalez
Dr. Mauricio Gonzalez clarifies that the United States has two FDA-approved medications specifically for MASH (metabolic dysfunction-associated steatohepatitis): resmetirom and semaglutide (Wegovy). However, for pure MASLD (metabolic dysfunction-associated fatty liver disease) without inflammation, there are currently no FDA-approved medications.
Summary
The transcript addresses the distinction between FDA-approved medications for different stages of metabolic liver disease. Dr. Gonzalez explains that there is often confusion about whether GLP-1 medications are prescribed specifically for liver disease or whether their liver benefits are secondary to treating type 2 diabetes or obesity. He clarifies the current FDA approval landscape: For MASH, which represents the more advanced, inflammatory stage of metabolic liver disease, two medications have received FDA approval. Resmetirom is described as a thyroxine receptor agonist that works in the liver and was the first medication to receive FDA approval for this indication. Semaglutide, marketed as Wegovy for weight loss, also has FDA approval for MASH. In contrast, for pure MASLD—the earlier stage characterized by fatty liver without significant inflammation—there are currently no FDA-approved medications available in the United States. This distinction is important for clinical practice and patient expectations regarding treatment options.
Key Insights
- Resmetirom was the first FDA-approved medication specifically for MASH, functioning as a thyroxine receptor agonist in the liver
- Semaglutide (Wegovy) has received FDA approval for MASH in addition to its obesity and diabetes indications
- There are currently no FDA-approved medications specifically for pure MASLD without the inflammatory component
- The United States has exactly two FDA-approved medications for MASH as of the time of this discussion
- The distinction between MASLD and MASH is clinically significant because medication approvals differ based on disease stage
Topics
Transcript
[0:00] Can you prescribe GLP-1s for MASLD or is the prescription for a type 2 diabetes or obesity and it has that effect on MASLD? >> In the United States, we have two medications that are FDA-approved for MASLD and MASH. For MASH, we have resmetirom and this is basically like an agonist of thyroxine receptor in the liver that was the first FDA-approved medication for that. Semaglutide, Wegovy, has FDA approval for MASH. For MASLD though, we don't, for pure MASLD. [0:30] But for MASH, we have these two medications.
Full transcript available for MurmurCast members
Sign Up to AccessMore from The Proof with Simon Hill
Cannabis & Sperm Quality: What the Research Actually Shows | EP#431
Cannabis use negatively impacts male fertility through multiple mechanisms including reduced sperm production, quality, and motility, with a dose-response relationship where daily use is considered problematic. Partners of cannabis users experience higher miscarriage rates, and IVF outcomes show lower embryo development rates in men who use cannabis, though the speaker advocates for moderation rather than absolute prohibition.
Can You Actually Reverse Liver Scarring? [Expert Explains] | EP#436
Liver fibrosis and scarring, previously thought to be irreversible, can actually be reversed even in advanced stages of steatotic liver disease. The liver has enormous regenerative potential and can recover from significant damage caused by alcohol or obesity, offering hope that early intervention can restore normal liver function.
Why Lower ApoB Longer Reduces Heart Disease Risk? | T. Dayspring & D. Soffer | EP#430
ApoB is established as a driver of atherosclerosis based on multiple types of evidence including clinical trials, observational studies, and genetic data. Lower ApoB levels for longer periods reduce heart disease risk, with clinical evidence showing continued cardiovascular benefit even when LDL-C is reduced from 70 to 15 mg/dL.
Do You Really Need Surgery for a Shoulder Tear? | Howard Luks | EP#438
Most joint and tendon pain in adults stems from lack of support, training, and proper loading rather than injury. Imaging often reveals age-related changes like labral tears that are normal findings over age 40-45 and don't necessarily require surgery, despite what social media doctors claim.
How Microplastics, Phthalates & PFAS May Affect Early Development & How to Reduce Exposure | EP#429
The episode discusses how microplastics, phthalates, and PFAS chemicals pose significant risks to child development during the first thousand days of life, with evidence showing specific harms like impacts on male fetal genital development and premature birth. The speaker emphasizes that systemic change through government regulation is necessary, while offering practical individual strategies to reduce exposure, primarily through avoiding heating food in plastic containers and switching to glass, steel, or natural materials.